CN104379597A - 改善膈肌功能的方法 - Google Patents

改善膈肌功能的方法 Download PDF

Info

Publication number
CN104379597A
CN104379597A CN201380018757.7A CN201380018757A CN104379597A CN 104379597 A CN104379597 A CN 104379597A CN 201380018757 A CN201380018757 A CN 201380018757A CN 104379597 A CN104379597 A CN 104379597A
Authority
CN
China
Prior art keywords
alkyl
imidazo
group
pyrazine
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380018757.7A
Other languages
English (en)
Chinese (zh)
Inventor
J·R·贾斯伯
F·马利克
D·T·威
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytokinetics Inc
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Priority to CN201810509450.1A priority Critical patent/CN108553467A/zh
Publication of CN104379597A publication Critical patent/CN104379597A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201380018757.7A 2012-04-02 2013-04-01 改善膈肌功能的方法 Pending CN104379597A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810509450.1A CN108553467A (zh) 2012-04-02 2013-04-01 改善膈肌功能的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261619261P 2012-04-02 2012-04-02
US61/619,261 2012-04-02
PCT/US2013/034824 WO2013151938A1 (en) 2012-04-02 2013-04-01 Methods for improving diaphragm function

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810509450.1A Division CN108553467A (zh) 2012-04-02 2013-04-01 改善膈肌功能的方法

Publications (1)

Publication Number Publication Date
CN104379597A true CN104379597A (zh) 2015-02-25

Family

ID=49300969

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380018757.7A Pending CN104379597A (zh) 2012-04-02 2013-04-01 改善膈肌功能的方法
CN201810509450.1A Pending CN108553467A (zh) 2012-04-02 2013-04-01 改善膈肌功能的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810509450.1A Pending CN108553467A (zh) 2012-04-02 2013-04-01 改善膈肌功能的方法

Country Status (15)

Country Link
US (2) US20150065525A1 (https=)
EP (1) EP2834269A4 (https=)
JP (3) JP6345645B2 (https=)
KR (1) KR20160046693A (https=)
CN (2) CN104379597A (https=)
AU (2) AU2013243671B2 (https=)
BR (1) BR112014024552A2 (https=)
CA (1) CA2868507A1 (https=)
EA (1) EA031183B1 (https=)
HK (1) HK1206364A1 (https=)
IL (2) IL234885A0 (https=)
MX (1) MX354965B (https=)
PH (1) PH12014502217A1 (https=)
SG (2) SG10201701101YA (https=)
WO (1) WO2013151938A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
KR101951220B1 (ko) 2011-07-13 2019-02-22 싸이토키네틱스, 인코포레이티드 조합 als 치료법
CN111840294A (zh) * 2012-04-11 2020-10-30 赛特凯恩蒂克公司 改善对骨骼肌疲劳的抵抗力的方法
SI2941432T1 (en) 2012-12-07 2018-07-31 Vertex Pharmaceuticals Incorporated 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
EP2970240B1 (en) 2013-03-14 2018-01-10 Novartis AG 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
JP2016512815A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
WO2014143242A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
DK3077397T3 (da) 2013-12-06 2019-12-16 Vertex Pharma 2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf
HUE057533T2 (hu) 2014-04-29 2022-05-28 Cytokinetics Inc Eljárások vitálkapacitás csökkenésének gátlására
PL3152212T3 (pl) 2014-06-05 2020-06-15 Vertex Pharmaceuticals Inc. Radioznakowane pochodne związku 2-amino-6-fluoro-n-[5-fluoro-piridyn-3-ylo]-pirazolo[1,5-a]pirymidino-3-karboksamidu przydatne jako inhibitor kinazy atr, wytwarzanie tego związku i jego różnych postaci stałych
LT3157566T (lt) 2014-06-17 2019-08-12 Vertex Pharmaceuticals Incorporated Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį
JP6573618B2 (ja) * 2014-09-09 2019-09-11 アステラス製薬株式会社 尿失禁予防用及び／又は治療用新規医薬組成物
WO2016193844A1 (en) 2015-05-29 2016-12-08 Pfizer Inc. Novel heterocyclic compounds as inhibitors of vanin-1 enzyme
HK1258570A1 (zh) 2015-09-30 2019-11-15 Vertex Pharmaceuticals Inc. 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
BR112018016475A2 (en) 2016-02-12 2018-12-26 Cytokinetics, Incorporated tetrahydroisoquinoline derivatives
EP3484876A1 (en) 2016-07-14 2019-05-22 Pfizer Inc Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
JP7770928B2 (ja) * 2019-06-19 2025-11-17 エフ． ホフマン－ラ ロシュ アーゲー デジタルバイオマーカー
JP7687968B2 (ja) 2019-06-19 2025-06-03 エフ． ホフマン－ラ ロシュ アーゲー デジタルバイオマーカー
WO2020254344A1 (en) 2019-06-19 2020-12-24 F. Hoffmann-La Roche Ag Digital biomarker
WO2021007477A1 (en) 2019-07-11 2021-01-14 E-Scape Bio, Inc. Indazoles and azaindazoles as lrrk2 inhibitors
WO2022099011A1 (en) 2020-11-06 2022-05-12 Cytokinetics, Inc. Bicyclic 1,4-diazepanones and therapeutic uses thereof
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
TW202448488A (zh) * 2023-04-17 2024-12-16 美商雅利斯塔製藥公司 用於治療肌肉萎縮症及記憶損傷之方法及組合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1464057A (zh) * 2002-06-03 2003-12-31 北京大学 具有骨骼肌刺激活性和免疫调节作用的趋化素样因子超家族
US20070173465A9 (en) * 1995-10-11 2007-07-26 Monahan Sean D Expression of zeta negative and zeta positive nucleic acids using a dystrophin gene

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7201898B2 (en) * 2000-06-01 2007-04-10 The University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
JP2007501805A (ja) * 2003-08-08 2007-02-01 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ピリジルピペラジニルウレア
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
ES2558517T3 (es) * 2006-08-02 2016-02-04 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y métodos que comprenden imidazopirimidinas
US8299248B2 (en) * 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
KR20100044251A (ko) * 2007-08-15 2010-04-29 싸이토키네틱스, 인코포레이티드 특정 화학 물질, 조성물 및 방법
NL2001694C2 (en) * 2008-06-18 2009-12-22 Nasophlex B V Ear stimulator for producing a stimulation signal to an ear.
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) * 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070173465A9 (en) * 1995-10-11 2007-07-26 Monahan Sean D Expression of zeta negative and zeta positive nucleic acids using a dystrophin gene
CN1464057A (zh) * 2002-06-03 2003-12-31 北京大学 具有骨骼肌刺激活性和免疫调节作用的趋化素样因子超家族

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MICHELLE PFLUMM: "IN BRIEF：An emerging medicine may help boost the power of certain muscles in people with ALS including those needed for breathing", 《ALS THERAPY DEVELOPMENT INSTITUTE》 *

Also Published As

Publication number Publication date
EA031183B1 (ru) 2018-11-30
AU2013243671A1 (en) 2014-10-16
MX354965B (es) 2018-03-27
JP2015516957A (ja) 2015-06-18
US20170266192A1 (en) 2017-09-21
SG11201406270YA (en) 2014-10-30
KR20160046693A (ko) 2016-04-29
EP2834269A4 (en) 2015-12-30
US20150065525A1 (en) 2015-03-05
IL267876A (en) 2019-09-26
HK1206364A1 (en) 2016-01-08
EP2834269A1 (en) 2015-02-11
WO2013151938A1 (en) 2013-10-10
JP2020147607A (ja) 2020-09-17
AU2017272286B2 (en) 2019-05-09
AU2013243671B2 (en) 2017-09-21
PH12014502217A1 (en) 2015-01-12
AU2017272286A1 (en) 2018-01-04
JP2018131460A (ja) 2018-08-23
SG10201701101YA (en) 2017-04-27
BR112014024552A2 (pt) 2017-09-19
JP6345645B2 (ja) 2018-06-20
IL267876B (en) 2021-03-25
MX2014011881A (es) 2016-07-20
IL234885A0 (en) 2014-12-31
EA201491605A1 (ru) 2015-03-31
CA2868507A1 (en) 2013-10-10
CN108553467A (zh) 2018-09-21

Similar Documents

Publication Publication Date Title
CN104379597A (zh) 改善膈肌功能的方法
ES2627347T3 (es) Aza-heterociclos bicíclicos sustituidos y análogos como moduladores de sirtuina
CN102762570B (zh) 作为jak抑制剂的吡唑衍生物
JP7012152B2 (ja) Ｆｓｈｄの治療のためにｄｕｘ４および下流遺伝子発現を低減するｐ３８キナーゼ阻害剤
EP2935260A1 (de) Bet-proteininhibitorische dihydropyridopyrazinone
JP2019523233A (ja) ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
EA036013B1 (ru) Новые спиро[3h-индол-3,2'-пирролидин]-2(1h)-оновые соединения и производные в качестве ингибиторов mdm2-p53
US10287293B2 (en) Bicyclic heterocyclic compounds as PDE2 inhibitors
BR112020005934A2 (pt) inibidor de pde9 e uso do mesmo
CN104395458A (zh) 改善对骨骼肌疲劳的抵抗力
PT2809669T (pt) Pirroldicarboxamidas fundidas e seu uso como farmacêuticos
WO2017206962A1 (zh) Flt3激酶的新型抑制剂及其用途
JP7763538B2 (ja) Ｐａｒｐ７阻害剤及びその使用
EP3672957A1 (en) Pyrimidine derivatives as tropomyosin receptor kinase a (trka) inhibitors
JP7787893B2 (ja) Ｎａｍｐｔモジュレーターとして有用なピラゾール誘導体
CN102341107A (zh) 用于肿瘤疾病的联合治疗
KR102778078B1 (ko) 피라졸 유도체 및 이의 용도
HK1261324A1 (en) Methods for improving diaphragm function
JP2025517635A (ja) 二環式ピペラジノン及びその治療的使用
HK40083035B (zh) Parp7抑制剂及其用途
TW202604514A (zh) 作為pi3k 抑制劑之含稠合三環之化合物
CN121002030A (zh) 作为毒蕈碱型乙酰胆碱受体m4的正向别构调节剂的噻唑并吡啶衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20180822

Address after: American California

Applicant after: Cytokinetics Inc.

Address before: American California

Applicant before: Cytokinetics Inc.

Applicant before: J.R.Jasper

Applicant before: F.Malik

Applicant before: D*T*Wei

TA01 Transfer of patent application right
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150225

WD01 Invention patent application deemed withdrawn after publication